Exelixis
EXEL
#1678
Rank
C$13.97 B
Marketcap
$48.95
Share price
-0.88%
Change (1 day)
67.21%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.38

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.40. In 2022 the company made an earnings per share (EPS) of $0.80 a decrease over its 2021 EPS that were of $1.04.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.38-53.2%
2022$0.80-22.97%
2021$1.04100%
2020$0.52-65.09%
2019$1.49-53.91%
2018$3.24333.96%
2017$0.75-260.61%
2016-$0.46-58.75%
2015-$1.13-42.45%
2014-$1.965.3%
2013-$1.8643.48%
2012-$1.30-264.29%
2011$0.79-165.88%
2010-$1.20-32.54%
2009-$1.78-17.65%
2008-$2.1675.86%
2007-$1.23-25.64%
2006-$1.658.33%
2005-$1.52-42.86%
2004-$2.6630.34%
2003-$2.04-5.23%
2002-$2.16-0.65%
2001-$2.17-51.88%
2000-$4.51

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$4.93 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$4.48 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$2.57 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.59 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$19.94 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$19.85 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.62 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$14.09-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.18-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA